Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and pharmacological study of glucarpidase (CPG2) in healthy volunteers
jRCT2091220078Phase 1Completed
- Sponsor
- Hiroshi Kawamoto
- Start
- Jan 2012
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of glucarpidase (2 cohorts), sponsored by Hiroshi Kawamoto. Primary endpoint: Dose-limiting toxicity of CPG2 at planned dose levels. Started Jan 2012; status: completed.
02
Drugs
glucarpidase
Beyond the preview
Go deeper on jRCT2091220078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220078.